UK Biobank Pharma Project publishes early

UPPSALA, Sweden, June 21, 2022 (GLOBE NEWSWIRE) – Olink Holding AB (yr of publication) (Nasdaq: OLK) has introduced {that a} publication describing early outcomes of proteomics analysis performed by the UK’s Very important Pharma Proteins Undertaking (UKB-PPP) has been Publish it on-line to bioRxiv Prepress server, obtainable over right here.

The research is entitledGenetic regulation of human plasma protein in 54,306 UK Biobank individualsOlink® Discover 1536 and genome sequencing on 54,306 UK Biobank individuals to gather and analyze information from protein quantitative trait (pQTL) sitemaps for 1,463 proteins figuring out 10,248 main genetic associations, 85% of which haven’t been beforehand reported.

The outcomes of the UKB-PPP publication present an up to date genetic atlas of plasma proteins and supply the scientific neighborhood with an open-access protein supply of broad scope and unprecedented depth to assist elucidate the organic mechanisms underlying genetic discoveries. Measuring 1000’s of proteins at a inhabitants scale guarantees to enhance our understanding of the mechanisms underlying illness, thus accelerating the event of recent biomarkers and therapeutics. Moreover, the research highlights the strengths of Olink’s Discover assay for pQTL and downstream biodetection, with a excessive proportion, 82% of the proteins examined, after Commonwealth of Unbiased States Associations, proof for extremely particular Olink assays that measure supposed proteins.

“The landmark analysis by UKB-PPP members is a significant early step in harnessing the facility of next-generation proteins mixed with genetic info to enhance human well being,” John Hymer, CEO of Olink. “We’re very grateful that Olink’s Discover platform will be part of this large journey, and we eagerly await the complete dataset that will likely be launched to the scientific neighborhood by the tip of this yr.”

The UK Biobank Pharma Undertaking is a collaboration between Biobank within the UK and 13 biopharma corporations, and is at present conducting one of many world’s largest scientific research of blood protein biomarkers. The UK Biobank is an in depth biomedical database and analysis useful resource containing in-depth genetic and well being info from half one million UK individuals. The database is globally accessible to researchers and authorized scientists who conduct very important analysis in the commonest and life-threatening illnesses. The UKB-PPP goals to allow a greater understanding of illness biology and help the event of progressive medicine for more practical therapies.

Olink Investor Contact
Jean Medina, CFA
Vice President of Investor Relations and Capital Markets
Cell: +1617802 4157

Olink Media Contact
Andrea Brander
Company Communications Supervisor
Cell: +46768775275

About Olink
Olink Holding AB (Nasdaq: OLK) is an organization devoted to accelerating proteins together with the scientific neighborhood, throughout a number of illness areas to allow new discoveries and enhance sufferers’ lives. Olink offers a platform of services deployed throughout main biopharmaceutical corporations and main scientific and educational establishments to deepen understanding of human biology in actual time and advance well being care within the twenty first century via highly effective and impactful science. The corporate was based in 2016 and is nicely established throughout Europe, North America and Asia. Ulink is headquartered in Uppsala, Sweden. Study extra about Olink over right here.

forward-looking statements
This press launch comprises forward-looking statements which might be primarily based on administration’s beliefs and assumptions and on info at present obtainable to administration. All statements on this launch aside from statements of historic details are forward-looking statements, together with statements concerning our 2022 income projections, our exterior purposes, our capability to develop, market and obtain market acceptance of our present and deliberate services, analysis and improvement efforts, and different issues regarding enterprise methods. Our enterprise, capital use, outcomes of operations and monetary place, and plans and targets for future operations. In some circumstances, you might establish forward-looking statements by the phrases “could,” “will,” “may,” “will,” “ought to,” “count on,” “intend,” “plan,” “count on,” “consider.” , “estimate”, “count on”, “mission”, “potential”, “persevering with”, “ongoing” or unfavourable for these or different comparable phrases, though not all forward-looking statements comprise these phrases. These statements contain dangers, uncertainties and different elements that would trigger precise outcomes, ranges of exercise, efficiency or achievements to vary materially from the data offered or included in these forward-looking statements. These dangers, uncertainties and different elements are described beneath the caption “Danger Elements” on our Kind 20-F (Fee File Quantity 001-40277) and elsewhere in paperwork we file with the Securities and Alternate Fee every so often. We warning you that forward-looking statements are primarily based on a mix of details and elements at present identified to us and our expectations for the longer term, of which we can’t be sure. Consequently, the forward-looking statements might not be correct. The forward-looking statements contained on this press launch characterize our views as of the date of this launch. We don’t undertake to replace any forward-looking statements for any purpose, besides as required by regulation.